Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mylan Nv Ord Shs (MYL) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 19,900,560
  • Shares Outstanding, K 534,910
  • Annual Sales, $ 9,429 M
  • Annual Income, $ 848 M
  • 36-Month Beta 1.09
  • Price/Sales 1.92
  • Price/Book 1.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.17 +2.49%
on 01/12/17
40.08 -7.51%
on 01/04/17
-0.22 (-0.59%)
since 12/20/16
3-Month
33.60 +10.33%
on 11/03/16
40.50 -8.47%
on 11/09/16
-0.54 (-1.44%)
since 10/20/16
52-Week
33.60 +10.33%
on 11/03/16
54.23 -31.64%
on 01/26/16
-14.33 (-27.88%)
since 01/20/16

Most Recent Stories

More News
Examining Volkswagen and Fiat Chrysler's Emissions Cheating Scandals

On today's episode of the Zacks Friday Finish Line podcast, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week's biggest story: the resolution of Volkswagen's emission cheating scandal...

Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks Bull and Bear of the Day

Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks Bull and Bear of the Day

Blog Coverage Expensive EpiPen Proves Costly for Mylan as Cigna Drops it from Coverage List; Opts for Generic Version

LONDON, UK / ACCESSWIRE / January 13, 2017 / Active Wall St. blog coverage looks at the headline from insurance major Cigna Corp. (NYSE: CI) and Mylan N.V. (NASDAQ: MYL) as the former Company dropped Mylan's...

Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News

The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.

Hess and Fiat Chrysler drop while Straight Path soars

NEW YORK (AP) — Stocks that moves substantially or traded heavily Thursday:

Stock Market Roundup, Jan. 12: AMZN Jobs, FCAU Cheating, AKS & X Tank

As investors continued to worry about President-elect Trump's targeting of the pharma industry, new concerns about U.S. industrial stocks help drag the markets down in morning trading Thursday. Nevertheless,...

CVS Debuts Cheap EpiPen Alternative

On Thursday, leading drug store chain CVS Health Corp. (CVS) announced that it is now selling a cheaper alternative to Mylan's (MYL) EpiPen.

CVS generic competitor to EpiPen, sold at a 6th the price

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of...

Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.

Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.

Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again

Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Support & Resistance

2nd Resistance Point 37.62
1st Resistance Point 37.35
Last Price 37.07
1st Support Level 36.80
2nd Support Level 36.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.